Yes, type 1 diabetes is an autoimmune disease. The immune system mistakenly attacks and destroys the insulin-producing cells in the pancreas, eventually leaving the body unable to regulate blood sugar on its own. An estimated 9.2 million people worldwide live with type 1 diabetes, and over 500,000 new cases were diagnosed globally in 2024.
How the Immune System Destroys Insulin-Producing Cells
In a healthy pancreas, clusters of cells called islets contain beta cells that produce insulin. In type 1 diabetes, the immune system’s T cells infiltrate these islets and kill the beta cells through two main routes. One is direct contact: a type of immune cell called a CD8 T cell locks onto a beta cell and releases toxic molecules (perforin and granzyme) that punch holes in it and trigger cell death. The other is chemical warfare: both CD4 and CD8 T cells release inflammatory signaling molecules that are directly toxic to beta cells.
These signals also activate another type of immune cell, macrophages, which produce their own wave of toxic compounds. This creates a destructive feedback loop: more inflammation draws in more immune cells, which kill more beta cells, which fuels more inflammation. The visible result of this process, an inflammatory lesion in and around the islets, is called insulitis. It’s the pathological hallmark of type 1 diabetes.
By the time symptoms appear, a substantial portion of the beta cells have already been destroyed. That’s why the disease often seems to come on suddenly even though the autoimmune process has been quietly running for months or years.
Genetics Set the Stage
Type 1 diabetes has a strong genetic component, and the biggest risk factor sits in a set of genes called HLA, which help the immune system distinguish the body’s own cells from invaders. Two specific gene variants, commonly abbreviated DR3 and DR4, confer the highest risk. People who inherit one copy of each (the DR3/DR4 combination) have roughly 16 times the odds of developing type 1 diabetes compared to the general population. Inheriting two copies of either DR3 or DR4 alone raises risk by about five to six times.
But genetics alone don’t seal the deal. Most people with high-risk HLA genes never develop the disease, which points to environmental triggers that tip the balance.
Environmental Triggers That May Start the Process
Viral infections are the leading environmental suspects. Enteroviruses, particularly a strain called Coxsackievirus B4, show up more frequently in people who go on to develop type 1 diabetes. Enterovirus infections are more common in siblings who develop the disease compared to those who don’t, and researchers have observed a timing link between signs of enterovirus infection and the first appearance of autoantibodies in children with genetic susceptibility.
One proposed explanation is molecular mimicry: a protein on the virus looks similar enough to a protein on beta cells (GAD, which the immune system later targets) that the immune response to the virus accidentally trains itself against the body’s own tissue. Another possibility is that the viral infection simply creates enough local inflammation in the pancreas to wake up immune cells that were already primed to attack beta cells. Coxsackievirus B4 has a known preference for infecting beta cells directly, which may amplify either pathway. Other viruses linked to type 1 diabetes include rotavirus, mumps, and cytomegalovirus, though the evidence is strongest for enteroviruses.
The Three Stages of Type 1 Diabetes
Type 1 diabetes doesn’t begin the day you start needing insulin. A joint scientific statement from JDRF, the Endocrine Society, and the American Diabetes Association defines three stages that reframe the disease as a continuum.
- Stage 1: Two or more islet autoantibodies are present in the blood, but blood sugar levels are completely normal. There are no symptoms. The autoimmune process is active, but enough beta cells remain functional.
- Stage 2: Autoantibodies are still present, and blood sugar levels have started to become abnormal, such as fasting glucose at or above 100 mg/dL or an A1C of 5.7% or higher. There are still no obvious symptoms, but the loss of beta cell function is progressing.
- Stage 3: This is the classic clinical diagnosis, with symptoms like excessive thirst, frequent urination, unexplained weight loss, and fatigue. Some people first present in diabetic ketoacidosis, a dangerous buildup of acids in the blood.
Screening studies in children suggest that about 0.3% of the pediatric population is in a presymptomatic stage at any given time. Of those, roughly 82% are in Stage 1, 7% in Stage 2, and 11% have undiagnosed Stage 3 disease. This staging matters because it opens a window for early intervention before symptoms ever develop.
How Autoantibodies Confirm the Diagnosis
The autoantibodies the immune system produces against beta cell proteins serve as both a diagnostic tool and a crystal ball. Four are used in clinical practice:
- Insulin autoantibodies (IAA): Almost always the first to appear in young children. Their levels correlate with how quickly the disease progresses. However, they’re frequently negative in teenagers and adults at the time of diagnosis.
- GAD65 autoantibodies: The most common in adults. A drawback is that GAD65 tests have a 3 to 5% false-positive rate in people without diabetes, which can complicate diagnosis when it’s the only antibody detected.
- IA-2 autoantibodies: The most disease-specific of the four, with a strong signal that makes testing reliable. Their presence is tied to the highest risk of progressing to clinical diabetes.
- ZnT8 autoantibodies: Also highly specific and particularly useful for characterizing autoimmune diabetes in adults.
Having two or more of these autoantibodies is the threshold for identifying someone in the presymptomatic stages. A single positive result, especially for GAD65, can sometimes be a false alarm, particularly in older or overweight adults who might otherwise look like they have type 2 diabetes. The presence of multiple autoantibodies is associated with extreme risk of eventually developing clinical type 1 diabetes.
LADA: The Slow-Burning Version
Not every autoimmune attack on beta cells moves at the same speed. Latent autoimmune diabetes in adults, or LADA, involves the same type of immune destruction but progresses much more slowly. People with LADA typically have autoantibodies at lower levels, fewer high-risk gene variants, and a milder initial presentation that often gets misdiagnosed as type 2 diabetes. They may manage for months or years on oral medications before eventually needing insulin.
One reason for the slower progression appears to be differences in the type of immune response. LADA tends to involve a less aggressive antibody profile that doesn’t destroy beta cells as rapidly. It’s immunologically the same disease as classic type 1 diabetes, just on a longer timeline.
A Treatment That Can Delay Onset
Because type 1 diabetes now has defined presymptomatic stages, a new category of treatment has emerged: drugs that slow the immune attack before symptoms start. Teplizumab, approved as the first therapy of its kind, targets the T cells responsible for beta cell destruction. In clinical trials, people treated with teplizumab took a median of 50 months to progress to Stage 3 diabetes, compared to 25 months for those who received a placebo. That’s roughly two extra years of life without needing insulin.
This treatment is specifically for people already identified as being in the presymptomatic stages, which underscores why screening with autoantibody tests has become increasingly important, especially for relatives of people with type 1 diabetes.
Who Gets Type 1 Diabetes
Type 1 diabetes was long considered a childhood disease, but the data tells a different story. Of the roughly 503,000 new cases diagnosed globally in 2024, 56.5% occurred in adults. Incidence in children and adolescents ranges from 5 to 50 per 100,000 depending on the country, with an average of about 14 per 100,000 annually. In adults aged 20 to 39, rates in high-income countries range from 5 to 17 per 100,000.
The disease is also becoming more common. Diagnosis rates in children and young people have increased by 1.5% to 3.4% per year over the past three decades. Finland has seen some of the sharpest increases, with incidence rising nearly 17% over a recent study period spanning 1994 to 2021. The reasons behind this rise remain unclear, though changes in early childhood viral exposures and other environmental factors are leading hypotheses.